realstrippoker|复宏汉霖现涨超5% HLX22的国际多中心III期临床试验美国获批

Gaming 2024年05月07日 12:59 8 editor

Fuhong Hanlius (02696) rose 5.5 percent in early tradingrealstrippoker.05%, currently quoted at HK$17.46, with a turnover of HK$3.791 million.

Fuhong Hanlius announced that the company's innovative anti-HER2 monoclonal antibody HLX22realstrippokerThe international multi-center Phase III new drug clinical trial (IND) application has been cleared by the U.S. FDA and is intended to be used in combination with trastuzumab and chemotherapy for the first-line treatment of HER2-positive advanced gastric cancer. Currently, no similar HER2 dual-targeted therapy for the treatment of HER2-positive gastric cancer has been approved for marketing in the world.